ATE310512T1 - Verwendung von lipoxinen zur inhibierung von tnf- alpha initiierter gegenreaktion - Google Patents

Verwendung von lipoxinen zur inhibierung von tnf- alpha initiierter gegenreaktion

Info

Publication number
ATE310512T1
ATE310512T1 AT00917903T AT00917903T ATE310512T1 AT E310512 T1 ATE310512 T1 AT E310512T1 AT 00917903 T AT00917903 T AT 00917903T AT 00917903 T AT00917903 T AT 00917903T AT E310512 T1 ATE310512 T1 AT E310512T1
Authority
AT
Austria
Prior art keywords
lipoxins
initiated
counterreaction
alpha
inhibit tnf
Prior art date
Application number
AT00917903T
Other languages
English (en)
Inventor
Charles N Serhan
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of ATE310512T1 publication Critical patent/ATE310512T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT00917903T 1999-03-18 2000-03-14 Verwendung von lipoxinen zur inhibierung von tnf- alpha initiierter gegenreaktion ATE310512T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12520599P 1999-03-18 1999-03-18
PCT/US2000/006582 WO2000054767A1 (en) 1999-03-18 2000-03-14 Use of lipoxin compounds for inhibiting of tnf-(alfa) initiated neutrophil response

Publications (1)

Publication Number Publication Date
ATE310512T1 true ATE310512T1 (de) 2005-12-15

Family

ID=22418647

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00917903T ATE310512T1 (de) 1999-03-18 2000-03-14 Verwendung von lipoxinen zur inhibierung von tnf- alpha initiierter gegenreaktion

Country Status (11)

Country Link
US (6) US6387953B1 (de)
EP (1) EP1165066B1 (de)
JP (1) JP4440481B2 (de)
AT (1) ATE310512T1 (de)
AU (1) AU775140B2 (de)
CA (3) CA2615917C (de)
DE (1) DE60024242T2 (de)
DK (1) DK1165066T3 (de)
ES (1) ES2249257T3 (de)
HK (1) HK1043307B (de)
WO (1) WO2000054767A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
CA2365204C (en) * 1999-03-18 2009-10-27 Brigham And Women's Hospital Lipoxin compounds and their use
EP2236140A1 (de) 1999-03-18 2010-10-06 The Brigham and Women's Hospital, Inc. Regulierung der Phospholipase d Aktivität
CA2615917C (en) * 1999-03-18 2011-10-04 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of tnf-(alpha)initiated neutrophil response
EP1762557B1 (de) 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-ausgelöste Lipidmediatoren
EP1268393A2 (de) 2000-03-20 2003-01-02 Trustees Of Boston University Lipoxinanaloge und verfahren zur behandlung von periodontalen erkrankungen
GB2362140B (en) * 2000-05-12 2003-03-05 Autoliv Dev Improvements in or relating to an apparatus for a method of folding an air-bag
EP1406698B1 (de) * 2001-03-02 2008-10-29 The Brigham and Women's Hospital Lipoxin analoge als neue inhibitoren der angiogenese
US8722654B2 (en) 2001-03-02 2014-05-13 The Brigham And Women's Hospital, Inc. Lipoxin analogs as novel inhibitors of angiogenesis
WO2003039533A1 (en) 2001-11-06 2003-05-15 The Brigham And Women's Hospital, Inc. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
EP1911448B1 (de) * 2001-11-06 2013-01-02 The Brigham and Women's Hospital, Inc. Aspirin-ausgelöste Lipoxine und ihre stabilen Analoga in der Behandlung von Asthma und entzündlichen Atemwegserkrankungen
US6831186B2 (en) * 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
EP2361622A1 (de) * 2001-12-18 2011-08-31 The Brigham and Women's Hospital Verwendung von Lipoxinanaloga für Förderung der Zellverteidigung gegen gramnegative Infektionen
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7902257B2 (en) * 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
AU2003258194B2 (en) * 2002-08-12 2009-11-12 The Brigham And Women's Hospital, Inc. Resolvins: biotemplates for therapeutic interventions
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
AU2005216298B2 (en) * 2004-02-26 2010-09-02 Baylor Research Institute Compositions and methods for the systemic treatment of arthritis
EP1755537A4 (de) * 2004-04-14 2009-12-09 Univ Boston Verfahren und zusammensetzungen zur prävention oder behandlung von periodontopathien
US8273792B2 (en) 2005-10-03 2012-09-25 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
US8636986B2 (en) * 2005-11-18 2014-01-28 The Forsyth Institute Treatment and prevention of bone loss using resolvins
US7906678B2 (en) 2006-12-04 2011-03-15 Bayer Schering Pharma Aktiengesellschaft Crystalline potassium salt of lipoxin A4 analogs
WO2011050126A1 (en) * 2009-10-21 2011-04-28 University Of Medicine And Dentistry Of New Jersey Method for treating sepsis or septic shock
CN110709138A (zh) 2017-01-31 2020-01-17 布里格姆及妇女医院股份有限公司 Alx受体配体定义炎症性疾病的生化内型
ES2986149T3 (es) 2018-10-09 2024-11-08 Univ Rochester Tratamiento de trastornos vulvovaginales

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
DE69435125D1 (de) 1993-06-15 2008-10-02 Brigham & Womens Hospital Lipoxinverbindungen mit verlängerter halbwertszeit
US5441951A (en) * 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
WO1995001179A1 (en) * 1993-06-29 1995-01-12 Brigham & Women's Hospital Modulation of inflammation related to columnar epithelia
CA2365204C (en) * 1999-03-18 2009-10-27 Brigham And Women's Hospital Lipoxin compounds and their use
CA2615917C (en) * 1999-03-18 2011-10-04 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of tnf-(alpha)initiated neutrophil response
EP2236140A1 (de) * 1999-03-18 2010-10-06 The Brigham and Women's Hospital, Inc. Regulierung der Phospholipase d Aktivität

Also Published As

Publication number Publication date
HK1043307B (en) 2006-02-03
CA2367909A1 (en) 2000-09-21
US20020132847A1 (en) 2002-09-19
US6710084B2 (en) 2004-03-23
HK1043307A1 (en) 2002-09-13
US20080312323A1 (en) 2008-12-18
DE60024242D1 (de) 2005-12-29
US6387953B1 (en) 2002-05-14
AU3880600A (en) 2000-10-04
US20020143069A1 (en) 2002-10-03
CA2615917A1 (en) 2000-09-21
AU775140B2 (en) 2004-07-22
EP1165066B1 (de) 2005-11-23
JP2002539159A (ja) 2002-11-19
US6703423B2 (en) 2004-03-09
CA2747376A1 (en) 2000-09-21
JP4440481B2 (ja) 2010-03-24
CA2367909C (en) 2008-02-12
DK1165066T3 (da) 2006-03-06
US7132451B2 (en) 2006-11-07
CA2615917C (en) 2011-10-04
WO2000054767A1 (en) 2000-09-21
US20040192785A1 (en) 2004-09-30
US20080081838A1 (en) 2008-04-03
DE60024242T2 (de) 2006-12-14
EP1165066A1 (de) 2002-01-02
ES2249257T3 (es) 2006-04-01

Similar Documents

Publication Publication Date Title
DE60024242D1 (de) Verwendung von lipoxinen zur inhibierung von tnf-alpha initiierter gegenreaktion
Myers et al. Mesenchymal stem cells at the intersection of cell and gene therapy
DE69734605D1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
AR049590A1 (es) Composiciones de limpieza humectantes suaves
DE60217367D1 (de) Nanopartikelzusammensetzungen enthaltend insulin
BR0211071A (pt) Conjugado polipeptìdico apresentando atividade de g-csf, método para preparar um conjugado de g-csf, composição, método para tratar um mamìfero sofrendo de um nìvel neutrofìlico insuficiente, e, uso do conjugado polipeptìdico
UA91321C2 (uk) Застосування модифікованого еритропоетину, що не є еритропоетичним, для захисту, відновлення і підсилення еритропоетинреактивних клітин, тканин і органів
SI1404811T1 (sl) Ogljikov monoksid izboljša rezultate pri presaditvi tkiva in organov ter prepreči apoptozo
BRPI0113477B8 (pt) proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula
ES2102196T3 (es) Periferializacion de celulas pluripotenciales hematopoyeticas.
AU2001263114A1 (en) Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
AU2000277238A1 (en) Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapy
PT1062321E (pt) Utilizacoes para celulas estaminais mesenquimais humanas nao autologas
ATE342729T1 (de) Modifizierter tumor-nekrosefaktor
DE59308257D1 (de) 25-carbonsäure-derivate in der vitamin d-reihe, diese derivate enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln
Khuituan et al. Fibroblast growth factor-23 negates 1, 25 (OH) 2D3-induced intestinal calcium transport by reducing the transcellular and paracellular calcium fluxes
DE60023660D1 (de) Antizymmodulatoren sowie deren verwendung
YU19399A (sh) Lokalni anestetik za spoljnu upotrebu
IT1271301B (it) Calconi naturali e sintetici e loro esteri ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno e formulazioni che li contengono
EA200200808A1 (ru) Модифицированные цитокины, предназначенные для применения в терапии рака
IL156628A (en) Use of nk t cells in medical preparation, preparations containing nk t cells and their use in the treatment of immune-related disorders
IL123642A (en) Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration
PT862452E (pt) Formulacao de estabilizacao para o ngf
ES2154311T3 (es) Quinoxalinas, procedimiento para su preparacion y su utilizacion.
MX2010003594A (es) Formas cristalinas de sal sodica de dmxaa.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1165066

Country of ref document: EP